Substance / Medication

Pazopanib

Overview

Active Ingredient
pazopanib
RxNorm CUI
714438
Labeler: Golden State Medical Supply, Inc.Updated: 2025-11-24T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended 5.1 [see Warnings and Precautions ()] .

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
Turjap Miroslav, Pelcová Marta, Gregorová Jana et al. · Ther Drug Monit · 2024
PMID: 38723115Meta-Analysis
Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).
Carroll Charlotte, Patel Nashita, Gunsoy Necdet B et al. · Future Oncol · 2022
PMID: 36399116Meta-Analysis
Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis.
Bongiovanni Alberto, Liverani Chiara, Recine Federica et al. · Front Oncol · 2020
PMID: 32318336Meta-AnalysisFull text (PMC)
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed Gregory T, Lee Sukdong, Brown Jamie N et al. · Clin Genitourin Cancer · 2019
PMID: 31585694Meta-Analysis
Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma.
Climent Miguel A, Muñoz-Langa José, Basterretxea-Badiola Laura et al. · Crit Rev Oncol Hematol · 2018
PMID: 29279098Meta-Analysis
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
Méndez-Vidal María José, Molina Áurea, Anido Urbano et al. · BMC Pharmacol Toxicol · 2018
PMID: 30477570Meta-AnalysisFull text (PMC)
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
Chellappan Dinesh Kumar, Chellian Jestin, Ng Zhao Yin et al. · Biomed Pharmacother · 2017
PMID: 29054093Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pazopanib (substance)
SNOMED CT
443763005
UMLS CUI
C1831796
RxNorm CUI
714438
Labeler
Golden State Medical Supply, Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.